Citations

Clear

6273 citation(s) found for "To, Andrew".

NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
Armstrong, Deborah K. , Alvarez, Ronald D. , Barroilhet, Lisa , Berek, Jonathan S. , Cristea, Mihaela , DeRosa, Marie, ElNaggar, Adam C. , Gray, Heidi J. , Hakam, Ardeshir, Jain, Angela, Liu, Joyce F. , Mahdi, Haider , Matei, Daniela , McHale, Michael , O’Malley, David M. , Penson, Richard T. , Percac‐Lima, Sanja , Ratner, Elena , Remmenga, Steven W., Sabbatini, Paul , Werner, Theresa L. , Zsíros, Emese , Burns, Jennifer L. , Engh, Anita M. , Matei, Daniela E , O'Malley, David M , Bakkum‐Gamez, Jamie N. , Behbakht, Kian , Berchuck, Andrew , Chen, Lee-may , Gershenson, David M. , Johnston, Carolyn , Leath, Charles A , McLean, Karen

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 7, 2019 | Volume: 17 | Issue: 8 | Pages: 896-909

10.6004/jnccn.2019.0039 | PMID 31390583 Get It

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years from diagnosis. A major challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. The best outcomes are observed in patients whose primary treatment includes complete resection of all visible disease plus combination platinum-based chemotherapy. Research efforts are focused on primary neoadjuvant treatments that may improve resectability, as well as systemic therapies providing improved long-term survival. These NCCN Guidelines Insights focus on recent updates to neoadjuvant chemotherapy recommendations, including the addition of hyperthermic intraperitoneal chemotherapy, and the role of PARP inhibitors and bevacizumab as maintenance therapy options in select patients who have completed primary chemotherapy.
Delineating the physiology of cryoballoon ablation
Su, Wilber , Tomaiko, Emrie, Tseng, Andrew , Su, Wilber W , Tseng, Andrew S.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | August 5, 2019 | Volume: 30 | Issue: 10 | Pages: 2088-2089

10.1111/jce.14096 | PMID 31379039 Get It

Autoimmune gait disturbance accompanying adaptor protein-3B2-IgG
Honorat, Josephe A., López‐Chiriboga, A. Sebastian , Kryzer, Thomas J., Komorowski, Lars , Scharf, Madeleine, Hinson, Shannon R., Lennon, Vanda A. , Pittock, Sean J. , Pittock, S J , Klein, Christopher J. , McKeon, Andrew

Mayo Clinic

Neurology | August 2, 2019 | Volume: 93 | Issue: 10 | Pages: No page available

10.1212/wnl.0000000000008061 | PMID 31371564 Get It

A Retrospective Case Series of Synovial Sarcoma of the Upper Extremity
Post, Joel M. , Folpe, Andrew L. , Wilke, Benjamin K. , Wilke, B K , Houdek, Matthew T. , Kakar, Sanjeev

Mayo Clinic

Sarcoma | August 1, 2019 | Volume: 2019 | Issue: No issue available | Pages: 1-7

10.1155/2019/8704936 | PMID 31467480 Get It

Purpose. Previous studies have grouped the treatment of axial and appendicular synovial sarcomas. The purpose of this study was to assess the prognostic variables of upper extremity synovial sarcomas (UESS) and compare the outcomes of those who underwent a nononcologic or inadvertent excision prior to definitive resection to those who underwent an initial oncologic resection. Methods. We reviewed the records of 23 UESS treated with definitive surgery at our institution between 1990 and 2014. There were 13 women and 10 men with a median age of 30 years (6–60) and median follow-up of 63 months (15–248). Prognostic variables, recurrence-free survival (RFS), and overall survival (OS) were then assessed. Results. Fifteen patients (65%) had a prior unplanned excision. Five patients required an amputation to obtain local control of disease. There were 3 observed local recurrences and 2 distant metastases at a median of 45 months from presentation. We found no difference in need for amputation, RFS, or OS between those who had undergone a planned excision and those who had an unplanned excision. Conclusion. While we were unable to find a significant difference in outcomes or amputation rates between those who underwent reexcision of a previously unplanned excision and those who underwent an initial planned resection, the high rate of unplanned excision is troubling and should remind practitioners to consider sarcoma in the differential of all upper extremity masses.
Can even experienced orthopaedic surgeons predict who will benefit from surgery when patients present with degenerative meniscal tears? A survey of 194 orthopaedic surgeons who made 3880 predictions
Graaf, Victor A. van de , Bloembergen, Coen H. , Noorduyn, Julia C. A. , Saris, Daniël B.F. , Poolman, Rudolf W. , van de Graaf, Victor A , Saris, Daniel Bf, Willigenburg, Nienke Willemien , Harris, Ian Andrew

Mayo Clinic

British Journal of Sports Medicine | August 1, 2019 | Volume: 54 | Issue: 6 | Pages: 354-359

10.1136/bjsports-2019-100567 | PMID 31371339 Get It

Objectives To examine the ability of surgeons to predict the outcome of treatment for meniscal tears by arthroscopic partial meniscectomy (APM) and exercise therapy in middle-aged patients. Design and setting Electronic survey. Orthopaedic surgeon survey participants were presented 20 patient profiles. These profiles were derived from a randomised clinical trial comparing APM with exercise therapy in middle-aged patients with symptomatic non-obstructive meniscal tears. From each treatment group (APM and exercise therapy), we selected five patients with the best (responders) and five patients with the worst (non-responders) knee function after treatment. 1111 orthopaedic surgeons and residents in the Netherlands and Australia were invited to participate in the survey. Interventions For each of the 20 patient profiles, surgeons (unaware of treatment allocation) had to choose between APM and exercise therapy as preferred treatment and subsequently had to estimate the expected change in knee function for both treatments on a 5-point Likert Scale. Finally, surgeons were asked which patient characteristics affected their treatment choice. Main outcomes The primary outcome was the surgeons’ percentage correct predictions. We also compared this percentage between experienced knee surgeons and other orthopaedic surgeons, and between treatment responders and non-responders. Results We received 194 (17%) complete responses for all 20 patient profiles, resulting in 3880 predictions. Overall, 50.0% (95% CI 39.6% to 60.4%) of the predictions were correct, which equals the proportion expected by chance. Experienced knee surgeons were not better in predicting outcome than other orthopaedic surgeons (50.4% vs 49.5%, respectively; p=0.29). The percentage correct predictions was lower for patient profiles of non-responders (34%; 95% CI 21.3% to 46.6%) compared with responders (66.0%; 95% CI 57.0% to 75.0%; p=0.01). In general, bucket handle tears, knee locking and failed non-operative treatment directed the surgeons’ choice towards APM, while higher level of osteoarthritis, degenerative aetiology and the absence of locking complaints directed the surgeons’ choice towards exercise therapy. Conclusions Surgeons’ criteria for deciding that surgery was indicated did not pass statistical examination. This was true regardless of a surgeon’s experience. These results suggest that non-surgical management is appropriate as first-line therapy in middle-aged patients with symptomatic non-obstructive meniscal tears. Clinical trial registration ClinicalTrials.gov Identifier: NCT03462134.
Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms
Satou, Akira , Bennani, N. Nora , Feldman, Andrew L.

Mayo Clinic

Expert Review of Hematology | July 31, 2019 | Volume: 12 | Issue: 10 | Pages: 833-843

10.1080/17474086.2019.1647777 | PMID 31365276 Get It

Synovial Sarcoma of the Nerve—Clinical and Pathological Features: Case Series and Systematic Review
Burks, S. Shelby , Puffer, Ross C. , Cajigas, Iahn , Valdivia, David , Spinner, Robert J. , Levi, Allan D. , Rosenberg, Andrew E.

Mayo Clinic

Neurosurgery | July 31, 2019 | Volume: 85 | Issue: 6 | Pages: E975-E991

10.1093/neuros/nyz321 | PMID 31435657 Get It

Abstract BACKGROUND Synovial sarcoma of the nerve is a rare entity with several cases and case series reported in the literature. Despite an improved understanding of the biology, the clinical course is difficult to predict. OBJECTIVE To compile a series of patients with synovial sarcoma of the peripheral nerve (SSPN) and assess clinical and pathological factors and their contribution to survival and recurrence. METHODS Cases from 2 institutions collected in patients undergoing surgical intervention for SSPN. Systematic review including PubMed and Scopus databases were searched for related articles published from 1970 to December 2018. Eligibility criteria: (1) case reports or case series reporting on SSPN, (2) clinical course and/or pathological features of the tumor reported, and (3) articles published in English. RESULTS From patients treated at our institutions (13) the average follow-up period was 3.2 yr. Tumor recurrence was seen in 4 cases and death in 3. Systematic review of the literature yielded 44 additional cases with an average follow-up period of 3.6 yr. From pooled data, there were 10 recurrences and 7 deaths (20% and 14%, respectively). Adjuvant treatment used in 62.5% of cases. Immunohistochemical markers used in diagnosis varied widely; the most common are the following: Epithelial membrane antigen (EMA), cytokeratin, vimentin, cluster of differentiation (CD34), and transducin-like enhancer of split 1 (TLE1). Statistical analysis illustrated tumor size and use of chemotherapy to be negative predictors of survival. No other factors, clinically or from pathologist review, were correlated with recurrence or survival. CONCLUSION By combining cases from our institution with historical data and performing statistical analysis we show correlation between tumor size and death.
Endovascular treatment decision in acute stroke: does physician gender matter? Insights from UNMASK EVT, an international, multidisciplinary survey
Ospel, Johanna M. , Kashani, Nima , Wilson, Alexis , Fischer, Urs , Sylaja, Pillai N., Turjman, Francis , Mitchell, Peter , Kim, Byung Moon , Cherian, Mathew , Heo, Ji Hoe , Baxter, Blaise, Podlasek, Anna , Foss, M , Menon, Bijoy K. , Hill, Michael D. , Saposnik, Gustavo , Ospel, Johanna Maria , Almekhlafi, Mohammed A , Hill, Michael D , Fischer, Urs , Campbell, Bruce , Yoshimura, Shinichi , Rabinstein, Alejandro A. , Almekhlafi, Mohammed , Demchuk, Andrew M. , Goyal, Mayank

Mayo Clinic

Journal of NeuroInterventional Surgery | July 30, 2019 | Volume: 12 | Issue: 3 | Pages: 256-259

10.1136/neurintsurg-2019-015003 | PMID 31363043 Get It

Background and purpose Differences in the treatment practice of female and male physicians have been shown in several medical subspecialties. It is currently not known whether this also applies to endovascular stroke treatment. The purpose of this study was to explore whether there are differences in endovascular treatment decisions made by female and male stroke physicians and neurointerventionalists. Methods In an international survey, stroke physicians and neurointerventionalists were randomly assigned 10 case scenarios and asked how they would treat the patient: (A) assuming there were no external constraints and (B) given their local working conditions. Descriptive statistics were used to describe baseline demographics, and the adjusted OR for physician gender as a predictor of endovascular treatment decision was calculated using logistic regression. Results 607 physicians (97 women, 508 men, 2 who did not wish to declare) participated in this survey. Physician gender was neither a significant predictor for endovascular treatment decision under assumed ideal conditions (endovascular therapy was favored by 77.0% of female and 79.3% of male physicians, adjusted OR 1.03, P=0.806) nor under current local resources (endovascular therapy was favored by 69.1% of female and 76.9% of male physicians, adjusted OR 1.03, P=0.814). Conclusion Endovascular therapy decision making between male and female physicians did not differ under assumed ideal conditions or under current local resources.
Liver Transplantation for Acute Liver Failure Secondary to Acute Sickle Intrahepatic Cholestasis
Racho, Ronald G., Krishna, Murli , Canabal, Juan, Canabal, Juan M, Keaveny, Andrew P.

Mayo Clinic

American Journal of Gastroenterology | July 30, 2019 | Volume: 115 | Issue: 6 | Pages: 809-809

10.14309/ajg.0000000000000345 | PMID 31365350 Get It

Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma
Wang, Yucai , Link, Brian K. , Witzig, Thomas E. , Maurer, Matthew J. , Allmer, Cristine, King, Rebecca L. , Feldman, Andrew L. , Ansell, Stephen M. , Nowakowski, Grzegorz S. , Witzig, T.E. , Feldman, Andrew L , Maurer, Matthew , Link, Brian K , Wang, Yucai , Habermann, Thomas M. , Slager, Susan L. , Cerhan, James R.

Mayo Clinic

Blood | July 26, 2019 | Volume: 134 | Issue: 16 | Pages: 1289-1297

10.1182/blood.2019000858 | PMID 31350266 Get It

Abstract In this month's CME article, an analysis of over 1300 patients with diffuse large B-cell lymphoma (DLBCL), Wang et al demonstrate that the approximately 13% of patients with concurrent indolent lymphoma at diagnosis had the same prognosis as those patients with isolated DLBCL.